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Abstract
Chemokines are important players in the migration of leukocytes to sites of injury and are also
involved in angiogenesis, development and wound healing. In this study, we performed microarray
analyses to identify chemokines that play a role during the inﬂammatory and repair phase after renal
ischemia/reperfusion (I/R) injury and investigated the temporal relationship between chemokine
expression, leukocyte accumulation and renal damage/repair. C57Bl/6 mice were subjected to
unilateral ischemia for 45 min and sacriﬁced 3 h, 1 day and 7 days after reperfusion. From ischemic
and contralateral kidney, RNA was isolated and hybridized to a microarray. Microarray results were
validated with quantitative real-time reverse transcription–PCR (QRT–PCR) on RNA from an
independent experiment. (Immuno)histochemical analyses were performed to determine renal
damage/repair and inﬂux of leukocytes. Twenty out of 114 genes were up-regulated at one or more
reperfusion periods. All these genes were up-regulated 7 days after I/R. Up-regulated genes included
CC chemokines MCP-1 and TARC, CXC chemokines KC and MIP-2a, chemokine receptors Ccr1 and
Cx3cr1 and related genes like matrix metalloproteinases. Microarray data of 1 and 7 days were
conﬁrmed for 17 up-regulated genes by QRT–PCR. (Immuno)histochemical analysis showed that the
inﬂammatory and repair phase after renal I/R injury take place after, respectively, 1 and 7 days.
Interestingly, chemokine expression was highest during the repair phase. In addition, expression
proﬁles showed a biphasic expression of all up-regulated CXC chemokines coinciding with the early
inﬂammatory and late repair phase. In conclusion, we propose that temporal expression of
chemokines is a crucial factor in the regulation of renal I/R injury and repair.
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Introduction
Renal ischemia/reperfusion (I/R) injury is a major cause of
acute (1) and chronic (2) renal failure. Ischemia is caused
by a sudden transient drop in blood ﬂow, frequently occur-
ring in shock, sepsis and during transplantation. Despite the
progresses made in health care, there are still only support-
ive therapies available for this major clinical problem. There-
fore, more insights into the mechanisms that regulate
ischemic injury and post-ischemic repair are needed.
Chemokines are chemotactic cytokines that are well
known for their ability to direct the migration and activation
of inﬂammatory cells. Chemokines can be divided into four
families based on their amino acid sequence in relation to
their cysteine moieties/differences in structure: CC, CXC,
CX3C and XC (reviewed in 3). Within these chemokine fami-
lies, functional homology exists; the CXC chemokines attract
mainly polymorphonuclear leukocytes to sites of acute
inﬂammation and the CC chemokines attract mainly mononu-
clear cells to sites of chronic inﬂammation (3).
Originally studied for their role in inﬂammation, it has now
become clear that chemokines are also involved in other
processes including angiogenesis, homeostasis, develop-
ment, migration of stem cells and wound healing (4,5). Dur-
ing renal I/R injury, inﬁltrated leukocytes (6–8) as well as all
types of renal cells including the tubular epithelial cells
(TEC) (9) start to produce chemokines. In different experi-
mental models of renal injury, the functional role of several
of these chemokines has already been investigated
(reviewed by Anders et al. 10). In lupus nephritis, for exam-
ple, blocking the interaction between Ccl2/MCP-1 and Ccr2
(11–13) or neutralizing Cx3cr1 (14) ameliorated the initiation
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nephropathy, Ccl2/MCP-1 deﬁciency (15, 16) or neutralizing
Cxcl10/IP-10 (17) decreased renal damage by reducing the
accumulation of macrophages or T cells, respectively. In
ischemic renal injury, a protective role of inhibiting Ccl2/
MCP-1 signaling (18, 19), neutralizing Cxcl1/KC (20) or
Cxcl2/MIP-2 (20) and blocking the chemokine receptor
Cx3cr1 (21, 22) during the inﬂammatory response has been
reported.
Although several studies have identiﬁed chemokines as
participants in renal diseases, there is little information
regarding their temporal expression. As tissue damage and
repair are dependent on a timely induction and suppression
of chemokines and are modulated by the inﬂux of leuko-
cytes, it is important to identify alterations in chemokine
expression during renal ischemic injury. Therefore, our aim
was to determine the expression of chemokines and their
receptors in a self-healing in vivo model of I/R injury during
different phases of I/R injury and to investigate the temporal
relationship between the altered chemokine expression with
renal damage/repair and inﬂux of leukocytes.
Methods
Mice
Seven-week-old male C57Bl/6 mice were purchased from
Charles River (Maastricht, The Netherlands) and housed
under speciﬁc pathogen-free conditions receiving food and
water ad libitum. All experimental procedures were
approved by the local Animal Care and Use Committee of
the University of Amsterdam, The Netherlands.
Renal I/R injury model
Unilateral and bilateral renal I/R injury was induced by
clamping, respectively, the right or both renal arteries for
45 min under general anesthesia [0.07 mg per 10 g mouse
of fentanyl citrate ﬂuanisone midazolam mixture, containing
1.25 mg ml
1 midazolam (Roche, Mijdrecht, The
Netherlands), 0.08 mg ml
1 fentanyl citrate and 2.5 mg ml
1
ﬂuanisone (Janssen Pharmaceuticals, Beerse, Belgium)].
The contralateral (left) or sham-operated kidney was used
as control when appropriate. After removal of the clamp, the
kidneys were inspected for restoration of blood ﬂow. For an-
algesic purposes, mice received a subcutaneous injection
of 50 lgk g
1 buprenorphin (Temgesic; Schering-Plough,
Brussels, Belgium) after closing the abdomen. Mice were
sacriﬁced several time points after surgery. Kidneys were
harvested and of each kidney one half was ﬁxed in formalin
and embedded in parafﬁn, and the other half was snap
frozen in N2(l) and stored at –80 C until further use.
(Immuno)histochemistry and antibodies
For (immuno)histological examination, 4 lm parafﬁn sections
were cut. Tubular injury was determined on sections stained
with periodic acid Schiff after diastase (PasD). Immunohisto-
chemical stainings to detect macrophages, neutrophils,
T cells, apoptosis and proliferation were performed using rat
anti-mouse F4/80 (Serotec, Oxford, UK), FITC-labeled anti-
mouse Ly-6G (BD Biosciences), rabbit anti-human CD3
(clone Sp7; Lab Vision Corp., Fremont, CA, USA), rabbit
anti-mouse active caspase 3 (Cell Signaling Technology,
Beverly, MA, USA) and rabbit anti-human Ki67 (clone Sp6;
Lab Vision Corp.) respectively. Macrophages, neutrophils,
T cells and apoptotic and proliferating TEC were counted in
the corticomedullar region in 10 randomly chosen, non-
overlapping high power ﬁelds (340 magniﬁcation).
RNA isolation and quality control
Total RNA was isolated from a one-fourth snap frozen kidney
using the TRIzol
  reagent (Invitrogen, Breda, The
Netherlands) method. The isolated RNA solution was treated
with DNAseI (Qiagen, Venlo, The Netherlands) to remove
any residual DNA. Subsequently, a RNA cleanup kit
(RNeasy; Qiagen) was used to obtain highly puriﬁed and
concentrated RNA samples.
As high-quality RNA is essential for acquiring good
microarray results, the concentration and purity of the RNA
were determined with a NanoDrop spectrophotometer
ND-1000 (NanoDrop Technologies, Wilmington, DE, USA)
and the ribosomal RNA band integrity was determined
on an Agilent 2001 BioAnalyzer
  (Agilent Technologies,
Amstelveen, The Netherlands). RNA samples used for
microarray experiments met all of the following criteria:
A260/A280 ratio >2.0, A260/A230 ratio >1.7 and a sharp
distinction at the small site of both the 18S and 28S ribo-
somal RNA bands/peaks.
Synthesis, labeling and ampliﬁcation of cRNA
The TrueLabeling-AMP
TM 2.0 kit (SuperArray, Frederick,
MD, USA) was used to amplify and label complementary
RNA (cRNA) according to the manufacturer’s protocol. In
short, from 10 lg of starting material (total RNA), comple-
mentary DNA (cDNA) was synthesized. Thereafter, cRNA
was synthesized and labeled with biotinylated-UTP
(Roche) during an incubation of 4 h to yield enough mate-
rial for one microarray per sample. The obtained cRNA
was puriﬁed using the ArrayGrade cRNA cleanup kit
(SuperArray) and the concentration was determined with
a NanoDrop.
Hybridization, detection and data analysis of microarrays
Mouse chemokines and receptors’ pathway-speciﬁc Oligo
GEArray
  microarrays from SuperArray were used. The
array membranes were pre-hybridized as described by the
manufacturer. Overnight, the membranes were hybridized
with 4 lg biotinylated cRNA at 60 C with continuous but
slow agitation. After washing, the Chemiluminescent Detec-
tion kit from SuperArray was used to visualize the biotiny-
lated cRNA on the membranes. The chemiluminescent array
image was captured with a CCD camera (LAS-3000; Fujiﬁlm,
Du ¨sseldorf, Germany) and analyzed with the web-based
GEArray Expression Analysis Suite (SuperArray). The
expression of genes was normalized toward a set of house-
keeping genes (Ppia, B2m and Hspcb) present on the
microarrays. The data are presented as fold increase in
ischemic kidney compared with the contralateral kidney. The
expression was considered to be up-regulated when the fold
increase was >2 and statistically signiﬁcant.
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The genes up-regulated 1 and/or 7 days after I/R injury were
selected to conﬁrm their upregulation by quantitative real-
time PCR on an independent data set obtained from mice
subjected to bilateral renal I/R injury or sham surgery. Primer
sequences were designed based on Primer3 software (23)
and obtained from the Universal ProbeLibrary Assay Design
Center (Roche). All primers (Table 1) were synthesized by
Sigma (Zwijndrecht, The Netherlands).
cDNA was synthesized using the M-MLV RT enzyme
kit (Invitrogen), oligo dT primers (Sigma) and RNAse inhibitor
(Applied Biosystem, Nieuwerkerk a/d IJssel, The
Netherlands) according to the manufacturer’s protocol.
Quantitative real-time reverse transcription PCR (QRT–PCR)
was performed on a LightCycler  480 System (Roche) using
LightCycler  480 SYBR Green I Master mix (Roche). Forty-
ﬁve cycles were carried out at an annealing temperature of
56–58 C. The starting concentrations of messenger RNAs
(mRNAs) were calculated by the LinRegPCR program (ver-
sion 9.30 beta) as described previously (24). The expression
of genes was normalized toward a set of housekeeping
genes (Ppia, B2m and Hspcb). The data are presented as
fold increase in ischemic kidney compared with sham kid-
ney. The expression was considered to be up-regulated
when the fold increase was >2 and statistical signiﬁcant.
Chemokine ELISA
Kidneys obtained from mice subjected to bilateral renal I/R
injury were homogenized in PBS containing 1% Triton X-100,
4 mM EDTA and 1% protease inhibitor cocktail (P8340,
Sigma). Concentrations of the chemokines Ccl2/MCP-1 and
Cxcl1/KC were measured in renal homogenates by speciﬁc
ELISA according to the manufacturer’s instructions (R&D,
Minneapolis, MN, USA). Chemokine levels were corrected
for the amount of protein present using the BioRad protein
assay (BioRad Laboratories, Veenendaal, The Netherlands)
with IgG as standard.
Statistical analysis
Results are expressed as mean 6 SEM, unless mentioned
otherwise. Data were analyzed by Mann–Whitney U-test or
unpaired Student’s t-test when appropriate. Values of
P < 0.05 were considered statistically signiﬁcant. All statisti-
cal analyses were performed using GraphPad Prism4
(GraphPad Software, San Diego, CA, USA).
Results
Microarray analysis of post-ischemic kidney
Microarray experiments were performed to determine the
temporal expression of several genes involved in renal I/R
injury. The analysis was limited to genes that express che-
mokines and chemokine receptors or related genes like
growth factors and cytokines. Of the total of 114 genes pres-
ent on the microarray, 20 were up-regulated at one or more
of the reperfusion periods. These transcripts were sorted
according to the reperfusion time as illustrated in the Venn
diagram (Fig. 1). In Table 2, the up-regulated genes are
expressed as a fold change compared with the contralateral
kidney. The up-regulated genes included CC chemokines
(e.g. Ccl2/MCP-1 and Ccl17/TARC), CXC chemokines (e.g.
Cxcl1/KC and Cxcl2/MIP-2a), chemokine receptors (Ccr1
and Cx3cr1) and other related genes like CSF1, matrix met-
alloproteinases (MMPs), TLR4 and the TLR adaptor molecule
MyD88 gene. Interestingly, all these genes were up-
regulated 7 days after I/R injury. In addition, six of these
genes were up-regulated 1 day after ischemia and two
genes (Cxcl2/MIP-2a and Cxcl10/IP-10) were up-regulated
Table 1. Primers used for real-time RT–PCR quantiﬁcation
GenBank Gene Primer forward Primer reverse
NM_009735 B2m cgagacatgtgatcaagcatc tggatttgtaattaagcaggttca
NM_011333 Ccl2 catccacgtgttggctca gatcatcttgctggtgaatgagt
NM_011333 Ccl6 ctccaagactgccatttcatt gcgacgatcttctttttcca
NM_011333 Ccl8 tcagcccagagaagctgact gggggatcttcagctttagtaca
NM_011331 Ccl12 ccaccatcagtcctcaggtatt cggacgtgaatcttctgctt
NM_011332 Ccl17 tgcttctggggacttttctg gaatggcccctttgaagtaa
NM_009912 Ccr1 ctgtgtggacaaaatactctgga tggggtaggcttctgtgaaa
NM_024217 Cklfsf3 atggcagggtttgtgctg tggagatgacgaagtagatgagg
NM_133978 Cklfsf7 accagagtggcctggtagc tgtaggacagccacaagctc
NM_007778 Csf1 ggctccaggaactctccaata atggaaagttcggacacagg
NM_009987 Cx3cr1 cgtgagactgggtgagtgac aaggaggtggacatggtgag
NM_008176 Cxcl1 ataatgggcttttacattctttaacc agtcctttgaacgtctctgtcc
NM_009140 Cxcl2 ccctggttcagaaaatcatcc cttccgttgagggacagc
NM_019932 Cxcl4 catctcctctgggatccatct ttttcctcccattcttcagg
NM_021274 Cxcl10 gctgccgtcattttctgc tctcactggcccgtcatc
NM_008302 Hspcb tccctcatcatcaacactttct gctctcatatcgaatcttgtcca
NM_008360 Il18 catgtacaaagacagtgaagtaagagg tttcaggtggatccatttcc
NM_008610 MMP2 ataacctggatgccgtcgt tcacgctcttgagactttgg
NM_010810 MMP7 ttctgctttgtgtgtctgctg ccttctttgttttagagtcatgagg
NM_010851 Myd88 tggccttgttagaccgtga aagtatttctggcagtcctcctc
NM_021297 Tlr4 ggactctgatcatggcactg ctgatccatgcattggtaggt
NM_008907 Ppia tgccagggtggtgactttac gatgccaggacctgtatgct
NM_008510 Xcl1 tcctgactttcctgggagtct ccgctgggtttgtaagttca
Chemokine expression in renal I/R injury 435at all reperfusion periods (i.e. 3 h, 1 and 7 days). We could
not detect any down-regulated genes in the ischemic kidney.
Validation of microarray results by QRT–PCR
The microarray data of 1 day and 7 days after I/R injury were
validated by means of QRT–PCR on mRNA obtained from an
independent experiment. Although the extent of change in
gene expression is not entirely the same, in general the
gene expression levels determined by microarray analysis
corresponded well with QRT–PCR data. Seventeen out of
the 20 genes up-regulated 7 days after ischemic injury could
be conﬁrmed (Fig. 2). One day after ischemic injury, we
could validate two out of the six genes. Interestingly, also
with QRT–PCR, we observed the highest expression of the
majority of up-regulated genes 7 days after ischemic injury.
These results conﬁrmed the microarray data obtained in the
present study.
Characterization of renal I/R injury
To correlate the chemokine expression with tubular damage
and repair and the inﬂux of different subsets of leukocytes,
(immuno)histological stainings were performed. Tubular dam-
age 3 h, 1 day and 7 days after unilateral I/R injury was visual-
ized with PasD staining (Fig. 3). Hallmarks of tubular damage
are dilation, loss of brush border, necrosis and cast deposi-
tion. Three hours after I/R, there is dilation of the tubules and
edema in the interstitial space. After 1 day, the tubular dam-
age is increased, the tubules show extensive coagulative
necrosis characterized by the presence of numerous ghost
cells in the tubules, loss of nuclei and decrease of staining.
Seven days after I/R injury, tubules are still abnormal although
coagulative necrosis is much less pronounced compared with
day 1. Important is the chaotic arrangement of TEC that are
dedifferentiated (absence of polarization, absence of brush
border, high nuclear/cytoplasm ratio) and the presence of
numerous mitotic ﬁgures, indicating high proliferation and
hence reparative processes within the tubules. Indeed, prolif-
eration of TEC was most abundant 7 days after I/R injury
(Fig. 4f) as determined by staining for Ki67 (Fig. 4a). The
number of apoptotic TEC was increased at all stages after
I/R injury with the highest number of apoptotic TEC 7 days
after I/R injury (Fig. 4e) as shown by quantitative analysis of
active caspase-3 immunostaining (Fig. 4a). Fig. 1. Venn diagram illustrating the number of genes that were
up-regulated >2-fold at each of the three reperfusion periods examined.
Table 2. Up-regulated genes 3 h, 1 day or 7 days after renal I/R injury, expressed as a fold change compared with the
contralateral kidney (n =4 )
Group Symbol Synonym Time after I/R injury
3 h 1 day 7 days
CC chemokines Ccl2 MCP-1 13.8 24.6
Ccl6 C10 12.2
Ccl8 MCP-2 26.8
Ccl12 MCP-5 3.2
Ccl17 TARC 34.5
CXC chemokines Cxcl1 KC 14.9 14.0
Cxcl2 MIP-2a 4.2 30.0 147.4
Cxcl4 PF4 26.1
Cxcl10 IP-10 3.9 8.9 14.2
Other chemokines Cklfsf3 Cmtm3 11.6
Cklfsf7 Cmtm7 5.8
Xcl1 Lymphotactin 10.6
Chemokine receptors Ccr1 MIP-1a/RANTES receptor 28.8
Cx3cr1 Fractalkine receptor 10.3
Other CSF1 M-CSF 5.6 8.6
IL18 IFNc-inducing factor 2.8 2.2
MMP2 72kDa type IV collagenase 7.8
MMP7 Matrilysin, uterine 220.1
MyD88 2.8
TLR4 31.8
436 Chemokine expression in renal I/R injuryThe inﬂux of neutrophils, macrophages and T cells was
determined by immunohistochemical staining (Fig. 4a).
Neutrophils were the ﬁrst inﬂammatory cells after I/R injury
with a peak after 1 day (Fig. 4b). Macrophages were almost
not detectable in the ischemic kidney until 7 days after I/R
injury (Fig. 4c). T cells could be detected at very low levels
at all time points, but were only signiﬁcantly increased 7 days
after I/R injury (Fig. 4d).
Biphasic expression of CXC chemokines and monophasic
expression of CC chemokines after I/R injury
Chemokines are mainly known for their ability to attract
inﬂammatory cells to sites of injury. Since we observed the
highest levels of chemokine expression at the stage of active
repair (i.e. 7 days after ischemic injury), we wanted to exam-
ine the temporal chemokines expression pattern in more
detail. The expression of the CC and CXC chemokines at
additional reperfusion periods after ischemic injury was eval-
uated to determine if there is a biphasic expression coincid-
ing with the inﬂammatory and reparative response after
ischemic injury.
In Fig. 5, the expression patterns of the up-regulated CC
and CXC chemokines after renal I/R injury are depicted. The
four CC chemokines were expressed in a monophasic fash-
ion with a clear peak 7 days after ischemic injury. In con-
trast, the CXC chemokines had a biphasic expression after
ischemic injury with the ﬁrst peak in the early (i.e. inﬂamma-
tory) phase and the second peak during the reparative
phase. The CXC chemokines Cxcl1/KC, Cxcl2/MIP-2a and
Cxcl10/IP-10 had the highest expression during the inﬂam-
matory phase. The inﬂux of neutrophils occurred along with
Fig. 2. Validation of the microarray results by quantitative real-time reverse transcription PCR (QRT–PCR). Expression of the up-regulated CC
chemokines, chemokine receptors, CXC chemokines, other chemokines and other genes 1 day (hatched bar) and 7 days (solid bar) after
ischemic injury compared with sham (open bar). Seventeen out of the 20 genes had an increased expression 7 days after ischemic injury. Four of
these genes were also up-regulated 1 day after ischemic injury. MyD88 and TLR4 (other genes) had no altered expression after I/R injury; IL18
expression was down-regulated 1 day after I/R injury. Data are expressed as mean 6 SEM, n = 7–8. *P < 0.05.
Chemokine expression in renal I/R injury 437the early peak of CXC chemokine mRNA expression. The
kinetics of the CC chemokines mRNA expression paralleled
those of the inﬂux of macrophages into the interstitium.
Ccl2/MCP-1 and Cxcl1/KC protein levels
To further examine whether the expression patterns of
selected chemokines identiﬁed by microarray and QRT–PCR
studies correlated with protein levels, we next performed
ELISA on total kidney homogenate. Since renal I/R injury is
characterized by the early inﬂux of neutrophils and a later
monocyte inﬂux, we determined protein levels of Cxcl1/KC
and Ccl2/MCP-1 that are potent chemoattractants for neutro-
phils (25) and monocytes (26), respectively. In accordance
with our mRNA data, Ccl2/MCP-1 protein level is highest
7 days after renal ischemia (Fig. 6a). Cxcl1/KC is signiﬁcantly
increased 1 and 7 days after renal ischemia compared with
sham (Fig. 6b). Furthermore, in line with our mRNA data,
Cxcl1/KC protein levels peak 1 day after renal I/R.
Discussion
In the present study, we identiﬁed chemokine, chemokine
receptor and chemokine-related genes whose expression is
affected in renal I/R injury. Instead of using whole genome
microarrays for which data analysis could be complicated,
we conducted pathway-speciﬁc oligonucleotide arrays that
contain 114 chemokines or related genes. Using QRT–PCR,
we validated the microarray results and ﬁnally obtained 18
genes with an altered expression 1 and/or 7 days after I/R
injury, of which the majority of these genes were chemo-
kines. Interestingly, all genes were signiﬁcantly up-regulated
during the repair phase, suggesting that they play a major
role in the resolution of ischemic injury.
Chemokines promote cell inﬁltration and activation ob-
served in many disease states (27). In addition, chemokines
are involved in other processes including angiogenesis,
homeostasis, development, migration of stem cells and
wound healing (4, 5). Therefore, chemokines are important
players in the initiation and progression of the inﬂammatory
response and in addition might have a great impact in the
reparative stage taking place after tissue injury. In the pres-
ent study, we found a tight temporal relationship between
chemokine expression and renal repair. Usually, chemokines
are regarded as playing an essential role in mediating leuko-
cyte recruitment and activation during initiation as well as
progression of renal inﬂammation. The current study how-
ever demonstrates that both CC and CXC chemokines are
mainly expressed during the reparative phase of renal I/R
injury. Additionally, we found that the time of inﬂux of the dif-
ferent types of leukocytes correlated with the upregulation
of certain chemokines.
In general, at an inﬂammatory or diseased site, neutrophils
are the ﬁrst leukocytes to be recruited. In line with previous
studies by our group (28–32), we currently found that neutro-
phils are the ﬁrst inﬂammatory cells inﬁltrating the damaged
site in renal I/R injury. These recruited neutrophils can not only
clear dead cells and debris but also amplify renal tissue injury
(33). The ELR
+ CXC chemokines (posses the ELR amino acid
motif) are the main neutrophil chemoattractants and play an
important role in regulating neutrophil chemotaxis and activa-
tion in ischemic tissue (34). Among them are Cxcl1/KC and
Cxcl2/MIP-2a, which are up-regulated early after ischemic in-
jury. The early expression of Cxcl1/KC was already described
in 1991 by Saﬁrstein et al. (35). Cxcl1/KC and Cxcl2/MIP-2a
have already been described as being important in the onset
of inﬂammatory response after renal I/R by regulating neutro-
phil inﬂux (20). In addition, the chemokine receptor Ccr1 is of
functional relevance for neutrophil recruitment during I/R (36).
Macrophages are believed to play a dual role in kidney
injury. Although widely recognized as contributing to the
pathogenesis of renal ﬁbrosis, glomerular and interstitial
macrophages may also play beneﬁcial, reparative and
matrix remodeling roles during tissue repair. Indeed, in this
study, we see signiﬁcantly more macrophages in the repair
phase (t = 7 days) of renal I/R. In addition, it has previously
been shown that adoptive macrophage transfer in the regen-
erative period not only leads to better tissue preservation but
also contributes to increased regeneration in renal I/R injury
(37). However, decreasing Ccr2-positive macrophage by
administering an antagonist for Ccl2/Mcp-1 early during re-
nal I/R injury is proposed as a proﬁtable therapy for I/R injury
in the kidney (18). In addition, Ccr2-deﬁcient mice had
decreased F4/80-positive cell inﬁltration and were protected
from acute tubular necrosis in renal I/R injury (19). The
majority of the macrophages express the receptor Cx3cr1
(38), suggesting that this receptor might mediate macro-
phage trafﬁcking to the kidney. In our I/R model, Cx3cr1 ex-
pression is signiﬁcantly increased 7 days after injury, the
peak moment of macrophage inﬂux. Furuichi et al. (38) has
shown that Cx3cr1 is up-regulated at later stages in renal I/
R injury and that Cx3cr1 deﬁciency attenuates macrophage
inﬂux 7 days after renal I/R injury. In contrast, Oh et al. (21)
concluded that early ischemic acute tubular necrosis (ATN)
is partially a Cx3cr1-dependent process as serum creati-
nine, ATN score and macrophage inﬁltration are reduced by
Cx3cr1 inhibition at early stages of post-ischemic
Fig. 3. Histological characteristics. Representative pictures of PasD-
stained contralateral (unaffected) kidney and kidney 3 hours (3h),
1 day (1d) and 7 days (7d) after I/R injury. The ﬁrst hallmarks of renal
injury are tubular dilation and interstitial edema (3h), thereafter loss
of brush border and extensive coagulative necrosis in the tubules
is observed (1d), followed by a decrease in tubular necrosis and
a chaotic arrangement of dedifferentiated TEC and presence of
numerous mitotic ﬁgures (7d). Original magniﬁcation: 340.
438 Chemokine expression in renal I/R injuryFig. 4. Quantiﬁcation of inﬁltrating leukocytes and TEC apoptosis and proliferation. (a) Representative pictures of neutrophil (Ly6),
macrophage (F4/80), T cell (CD3), apoptosis (active caspase-3) and proliferation (Ki67) immunostaining of contralateral kidney and kidneys
3 h, 1 day and 7 days after I/R injury. Original magniﬁcation: 340. (b) Neutrophils are increased at all three reperfusion periods, with the
highest numbers 1 day after ischemic injury. (c) Macrophages are only increased 7 days after ischemic injury. (d) T cells are present in low
amounts at all reperfusion periods, and only signiﬁcantly increased 7 days after ischemic injury. (e) The number of apoptotic TEC is
signiﬁcantly increased at all three reperfusion periods and peaks 7 days after ischemic injury. (f) The number of proliferating TEC is only
signiﬁcantly increased 7 days after ischemic injury. Positive cells are given per high power ﬁeld (hpf, 340 magniﬁcation). Data are expressed
as mean 6 SEM, n =4 .*P < 0.05.
Chemokine expression in renal I/R injury 439reperfusion. It is important to acknowledge the heterogeneity
of macrophages; functionally distinct subpopulations may
exist in the same tissue and play critical roles in both the ini-
tiation and recovery phases (reviewed in 39).
The numbers of Tcells in the post-ischemic kidney are low,
but they are signiﬁcantly increased 7 days after renal I/R injury.
This upregulation coincides with an increased expression of sev-
eral chemokines (e.g. Cxcl10/IP-10 and Ccl17/TARC) involved
in T-cell chemotaxis. Direct evidence supporting a role of Tcells
as both mediators and protectors of I/R in rodent models is
reviewed by Huang et al. (40). Recently, it has been shown
that kidney ischemia induces long-term T-cell inﬁltration (41).
However, the role of chemokines in T-cell inﬂux in post-
ischemic kidneys has not yet been studied in detail.
Our data suggest that chemokines are not solely linked to
the acute inﬂammatory response and the inﬁltration of different
subsets of leukocytes in the post-ischemic kidney. Especially,
the high expression of chemokines during the repair phase
(t = 7 days) and the fact that all up-regulated CXC
Fig. 5. Expression proﬁle of CC and CXC chemokines up to 14 days after renal ischemic injury. To obtain an expression proﬁle of the up-
regulated CC and CXC chemokines during the whole course of renal ischemic injury and post-ischemic repair, additional reperfusion periods
(2 h, 1, 3, 7 and 14 days) were analyzed by QRT–PCR. CC chemokine expression peaked only at 7 days after I/R injury. CXC chemokine
expression was biphasic, with a peak during the early inﬂammatory response (2 h and 1 day) and a second peak during the later repair phase
(3 and 7 days). Data are expressed as mean 6 SEM, n = 6–8.
Fig. 6. Renal Ccl2/MCP-1 and Cxcl1/KC protein levels after ischemic
injury. (a) Renal Ccl2/MCP-1 protein levels were signiﬁcantly up-
regulated 7 days after ischemic injury (solid bars) compared with
sham (open bar) and 1-day post-ischemia (hatched bars) kidney. (b).
Renal Cxcl1/KC protein levels were signiﬁcantly up-regulated
1 (hatched bar) and 7 (solid bar) days after renal ischemia compared
with sham kidney (open bar). Data are expressed as mean 6 SEM,
n = 4 (sham) and n = 9 (1 and 7 days). *P < 0.05 compared with
sham.
440 Chemokine expression in renal I/R injurychemokines had a biphasic expression coinciding with the
acute and reparative phases after renal I/R injury led us to
propose a pleiotropic role of chemokines during the different
phases after an ischemic insult in the kidney. For instance,
hepatocyte growth factor (HGF)-mediated Cxcl1/KC produc-
tion has been shown to inﬂuence the normal effects of HGF
on epithelial morphogenesis, suggesting that Cxcl1/KC can
act in an autocrine fashion in these cells, thereby playing
a beneﬁcial role in the repair process as well (42). In addition
to Cxcl1/KC, Cxcl2/MIP-2a has also been shown to stimulate
proliferation of epithelial cells (43). Conversely, Furuichi et al.
(44) showed that the induction of Cxcl10/IP-10 in ischemic
kidney inhibits tubular cell proliferation. This controversy can
be explained by the presence or absence of the ELR motif in
CXC chemokines. In general, ELR
+ CXC chemokines (e.g.
Cxcl1/KC and Cxcl2/MIP-2) have angiogenic properties while
ELR
– CXC chemokines (e.g. Cxcl4/PF4 and Cxcl10/IP-10)
behave as angiostatic (4). Besides, CXC chemokines inﬂu-
ence proliferation in several cell types including hepatocytes
(45), gastric epithelial cells (46) and intestinal epithelial (crypt)
cells (47). Apparently, chemokines integrate inﬂammatory
responses and reparative processes that play crucial role in
renal I/R injury. Interestingly, during the reparative phase,
there is presumably a tight balance between ELR
+ and ELR
–
CXC chemokines to regulate epithelial cell proliferation.
The chemokines Ccl6, Ccl8, Ccl12, Cxcl4, Cklfsf3, Cklfsf7
and Xcl1 are not discussed here. Their role in renal I/R injury
and repair remains to be elucidated. Based on their expression
proﬁle we hypothesize that these chemokines are involved in
the repair of the post-ischemic kidney. In addition, some other
genes were up-regulated after renal I/R injury. Among them
are MMP2 and MMP7. In general, MMPs degrade the extracel-
lular matrix (ECM), however, recently new biological roles of
MMPs by proteolytic action on a variety of non-ECM substrates
have been described (reviewed in 48).The increased expres-
sion of both MMPs during the reparative phase after renal I/R
injury suggests a role in remodeling tubular structure.
Functional studies in animal models of renal inﬂammatory
diseases have generated conﬂicting results with regard to
the role of chemokines (reviewed by Anders et al. 10, KI
2003). Our data indicate that these contradictory results
could merely reﬂect the time points at which the chemokines
were targeted. The analysis of temporal and spational che-
mokines expression will therefore be crucial for the design
of effective therapies.
In conclusion, our study shows the expression proﬁle of che-
mokines and related genes after renal I/R injury. Interestingly,
all these chemokines are signiﬁcantly increased during the re-
parative phase. A biphasic expression, coinciding with the
acute inﬂammatory and the later reparative phase, of the CXC
chemokines was observed. This study provides an important
resource for exploring new therapeutic targets for the treat-
ment of ischemic kidney injury and indicates that effective ther-
apeutic interventional strategies will strongly depend on the
exact time point at which the intervention takes place.
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